source
- Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offeringKardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…
- Kardigan secures $400 million IPO to fund three clinical-stage cardiovascular candidatesKardigan, a New Jersey biotech focused on heart disease, announced it raised $400 million in a Nasdaq initial public offering. The capital will be directed toward advancing three clinical-stage dr…